← All Biomarkers
HR+
2 drugs Predictive biomarker for patient selection in 9 indications
HR+ is a precision-medicine biomarker linked to 2 FDA-approved targeted drugs from 2 companies, spanning 9 indications including Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive, early breast cancer at high risk of recurrence, Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer as initial endocrine-based therapy, Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer with disease progression following endocrine therapy. Explore the targeted therapies, indications, testing methods, and companies developing HR+ drugs below.
Drugs Targeting HR+
| Drug | Company | Therapeutic Area |
| ENHERTU | DAIICHI SANKYO INC | Oncology |
| VERZENIO | Eli Lilly | Oncology |
HR+ Indications
Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive, early breast cancer at high risk of recurrence Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer as initial endocrine-based therapy Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer with disease progression following endocrine therapy Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting Unresectable or metastatic HER2-positive breast cancer Unresectable or metastatic hormone receptor-positive, HER2-low or HER2-ultralow breast cancer Unresectable or metastatic HER2-low breast cancer Unresectable or metastatic HER2-mutant non-small cell lung cancer Locally advanced or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma
